Public preview. Funding rounds, founders, and growth signals require a free account.
Unlock full profile
Isterian Biotech, Inc.
Isterian Biotech develops inhibitors targeting transglutaminase 2 (TG2) to address pathological protein crosslinking in fibrotic diseases such as idiopathic pulmonary fibrosis. The company's approach aims to prevent protein buildup in aged tissues and reverse fibrosis-related conditions.
SeedBiotechBrooklyn, NY1-10 employees
Total raised
$3.0M
Last round
Equity
$3.0M · Mar 2020
Stage
Seed
Status
Active
Founders & team
Growth signals
Track Isterian Biotech, Inc. on FlareSight
Get notified the moment Isterian Biotech, Inc. files a new round, hires execs, or shows traction signals.
Create free accountAbout this data
FlareSight surfaces funding data from SEC Form D filings within hours of submission. Browse our full startup funding database to find more recently funded companies.